



RECEIVED  
MAY 23 2003  
TECH CENTER 1600/2900

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450, on the date appearing below.

ELI LILLY AND COMPANY

By Linda M. Dunham

Date May 20, 2003

**REISSUE PATENT APPLICATION**  
**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Reissue Application of	)	
U.S. Patent No. 5,945,416	)	Confirmation No.:
	)	9165
Applicants: Shannon, et al.	)	Group Art Unit:
Application No.: 09/935,513	)	1617
Filed: August 22, 2001	)	Examiner:
For: METHOD FOR TREATING PAIN	)	Theodore J. Criares
Docket No.: X-10576A	)	

**REMARKS PURSUANT TO 37 C.F.R. § 1.111**

Commissioner for Patents  
Alexandria, VA 22313-1450

Sir:

In the Office Action of March 12, 2003, the Office rejected claims 1-44, 60-67, and 81-91 under various arguments which are individually considered by Applicants below. An Information Disclosure Statement and Terminal Disclaimer is submitted herewith. A clean set of pending claims 1-44, 60-67, and 81-91 is attached herewith in Appendix B for the Office's convenience.

**REMARKS**

An Information Disclosure statement was filed in the present reissue application on September 20, 2001, a copy of which is attached herewith. Applicants have not received the corresponding initialed Form 1449 indicating that the Office considered the references cited therein. Applicants therefore respectfully request that the Office provide such confirmation of consideration by returning the corresponding initialed Form 1449 to the Applicants.

Serial No. 09/935,513

In addition, Applicants wish to bring to the Office's attention that U.S. Patent No. 6,147,072, cited in the IDS first filed with this response, was filed as a Reissue Application on October 31, 2002 and was assigned Serial Number 10/285,890, Art Unit 1614.

**DOUBLE PATENTING REJECTION**

The Office rejected claims 1-44, 60-67, and 81-91 under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1, 4, and 5 of U.S. Patent No. 5,972,932. While Applicants do not necessarily agree with the Office's assessment of the claims under the obviousness-type double patenting rejection, Applicants provide, only in order to expedite prosecution, a terminal disclaimer pursuant to 37 C.F.R. § 1.321. Applicants further submit that the filing of this terminal disclaimer is not an admission or acquiescence by, nor shall act as an estoppel upon, the Applicants on the merits of the rejection. In addition, in order to clarify the record relating to the present double patenting rejection, Applicants submit that the body of claims 1 to 27, 60-67, and 81-89 defines a structurally complete invention and the preamble of said claims merely states an intended use for the invention.

**REQUEST FOR SUPPLEMENTAL DECLARATION**

Pursuant to 37 C.F.R. 1.175(b)(1), the Office asserted that a new reissue oath/declaration must be received before the present reissue application can be allowed. In compliance with this request, Application submit herewith a Supplemental Reissue Declaration which sets forth specific errors.

In view of the above remarks and documents attached herewith, Applicants submit that claims 1-44, 60-67, and 81-91 are in condition for allowance. Reconsideration and withdrawal of the rejections is respectfully requested and allowance of claims 1-44, 60-67, and 81-91 is kindly solicited.

Respectfully submitted,



Nelsen L. Lentz  
Attorney for Applicants  
Registration No. 38,537  
Telephone No. (317) 276-1207

Serial No. 09/935,513

Patent Division  
Eli Lilly and Company  
P. O. Box 6288  
Indianapolis, Indiana 46206-6288

May 16, 2003